Benzinga | Sep 23, 2020 08:04AM EDT

Biocept Announces Award Of Japanese Patent For Primer-Switch Mutation Detection And Amplification Improvement Platform Used To Detect Rare Cell Mutations In Tissue, Blood And Cerebrospinal Fluid

SAN DIEGO, Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the award of Japanese Patent No. 6734887, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for the Primer-Switch technology, which is useful for the detection of rare mutations, including cancer biomarkers, found in tissue, blood and cerebrospinal fluid using circulating tumor DNA (ctDNA) analysis through real-time PCR and associated analysis methods, including next-generation sequencing (NGS).